You are here: Home » Companies » Results
Business Standard

Zydus Cadila's Q3 PBT dips 32% to Rs 457 cr, revenue up marginally

Formulation sales in US up 16% sequentially to Rs 1,675 cr, rest-of-the-world biz consisting of multiple emerging markets grew by 21%

Vinay Umarji  |  Ahmedabad 

Zydus Cadilla, healthcare, Sentynl, Ahmedabad

Cadila Healthcare Ltd. (Zydus Cadila) has reported a consolidated profit before tax (PBT) of Rs 457.1 crore, down by 31.94 per cent for the third quarter ended December 31, 2019 on a year-on-year (YoY) basis, based on its filing with exchanges on Wednesday.

The company's consolidated PBT for Q3 of previous fiscal 2018-19 stood at Rs 671.7 crore. posted a marginal 1.3 per cent rise in its total revenue for Q3 of FY20, at Rs 3,658.2, crore, from Rs 3,608.9 crore for the corresponding period last year.

On Wednesday, stated that its formulations business in the US posted sales of Rs 1,675 crore, up 16 per cent on a QoQ basis while its Indian branded human formulations business grew by 9.6 per cent on a YoY basis. The company’s rest-of-the-world business comprising of multiple emerging markets grew by 21 per cent on a sequential basis.

In Q3 of FY'20, launched nine new products in the US including a Day One launch, even as it filed four additional abbreviated new drug applications (ANDAs) with the USFDA taking the cumulative number of ANDA filings to 386. Zydus Cadila also stated that it received eight new product approvals including two tentative approvals from the USFDA during Q3 of FY'20.

During the quarter, the company also launched the oral anti-diabetic agent, Vinglyn (Vildagliptin) and Vinglyn M (Vildagliptin plus Metfonnin) in India, the former being one of the most affordable brands of Vildagliptin for diabetic patients in India.

On the research front, the company filed a new drug application (NDA) of Saroglitazar Mg in Non-alcoholic Steatohepatitis (NASH) with the Drug Controller General of India (DCGI), a first with any regulatory authority across Asia and only the second across the globe for NASH indication.

The company also announced the second phase III DREAM-D trials of Desidustat, an lnvestigational New Drug (IND) targeted at treating anaemia in dialysis-dependent CKD (chronic kidney disease) patients, during Q3 of current fiscal 2019-20.

During the quarter, the Company received regulatory permission to conduct Phase-1 clinical trials for Hepatitis A and Hepatitis E Vaccines. Dossiers were also submitted to the DCGI for the Marketing Authorization of Pentavalent Vaccine, it stated.

Meanwhile, the company recently saw the USFDA conclude inspection of the manufacturing facility of one of its wholly-owned subsidiary Alidac Pharmaceuticals Ltd. The regulator had conducted inspection between January 27 and February 4, 2020 at the site that manufactures oncology injectables for regulated markets, with no observations being issued by USFDA.

First Published: Wed, February 05 2020. 18:01 IST
RECOMMENDED FOR YOU